NRAS and metastatic melanoma: In view of the previously described beneficial effect of MEK162 in NRAS-mutated metastatic melanoma, and knowing that our patient carried an activating NRAS mutation in his leptomeningeal melanocytosis lesion, we considered treatment of our patient with MEK162.